Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.9700 (4.19%) ($6.9700 - $6.9700) on Fri. Apr. 29, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.17% (three month average) | RSI | 35 | Latest Price | $6.9700(4.19%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.6% a day on average for past five trading days. | Weekly Trend | TGTX declines -13.9% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(75%) ARKG(70%) IBB(68%) ARKK(64%) IBUY(58%) | Factors Impacting TGTX price | TGTX will decline at least -3.085% in a week (0% probabilities). VIXM(-48%) VXX(-40%) UUP(-22%) TBT(-11%) USO(-5%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.085% (StdDev 6.17%) | Hourly BBV | 1.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-22.11(-417.22%) | Resistance Level | $8.33 | 5 Day Moving Average | $6.87(1.46%) | 10 Day Moving Average | $7.07(-1.41%) | 20 Day Moving Average | $8.33(-16.33%) | To recent high | -40.8% | To recent low | 6.3% | Market Cap | $883m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |